Logo
x

Search

Subscribe Now

Amgen

Amgen Reports 52 Weeks Data from P-II Trial of Maritide in Obese People with or without Type 2 Diabetes

Amgen Reports 52 Weeks Data from P-II Trial of Maritide in Obese People with or without Type 2 Diabetes

  • November 27, 2024
Amgen’s Otezla (Apremilast) is now Accessible in The US to treat Moderate to Severe Pediatric Plaque Psoriasis

Amgen’s Otezla (Apremilast) is now Accessible in The US to treat Moderate to Severe Pediatric Plaque Psoriasis

  • August 22, 2024
Amgen’s Blincyto (Blinatumomab) Receives the US FDA’s Approval to Treat B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)

Amgen’s Blincyto (Blinatumomab) Receives the US FDA’s Approval to Treat B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)

  • June 17, 2024
Amgen Reports the P-III (MITIGATE) Study Data of Uplizna (Inebilizumab-cdon) to Treat Immunoglobulin G4-Related Disease (IgG4-RD)

Amgen Reports the P-III (MITIGATE) Study Data of Uplizna (Inebilizumab-cdon) to Treat Immunoglobulin G4-Related Disease (IgG4-RD)

  • June 6, 2024
Amgen’s Bkemv (Biosimilar, Soliris) Receives the US FDA’s Approval for PNH & aHUS

Amgen’s Bkemv (Biosimilar, Soliris) Receives the US FDA’s Approval for PNH & aHUS

  • May 28, 2024
Amgen’s Imdelltra (Tarlatamab-dlle) Receives the US FDA’s Approval to Treat Extensive-Stage Small Cell Lung Cancer

Amgen’s Imdelltra (Tarlatamab-dlle) Receives the US FDA’s Approval to Treat Extensive-Stage Small Cell Lung Cancer

  • May 17, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.